Hiroomi Watabe

693 citations
28 papers · 590 indexed · h-index 14
Topics
Microbial Natural Products and Biosynthesis (7 papers)Antibiotic Resistance in Bacteria (6 papers)Cancer therapeutics and mechanisms (5 papers)

In The Last Decade

Hiroomi Watabe

27 papers receiving 556 citations

Peers

Hiroomi Watabe
Comparison fields: 5 of 83
  • Molecular Biology 292
  • Pharmacology 164
  • Epidemiology 95
  • Organic Chemistry 81
  • Immunology 80
Replace Junzo Mizoguchi with:
Junzo Mizoguchi Japan
Wdee Thienphrapa United States
Beth Andrews United States
Siegfried Raddatz Germany
Katsuhisa Nakata Japan
Xuefu You China
R. J. McRipley United States
Sufi Morshed Japan
Nassira Mahmoudi France
J. P. Rosselet United States
Hiroomi Watabe relative to Junzo Mizoguchi Japan Junzo Mizoguchi's profile →
Citations per field
00.5×10.5×
Junzo Mizoguchi · 1×
Citations per year

Countries citing papers authored by Hiroomi Watabe

Since Specialization
Citations

This map shows the geographic impact of Hiroomi Watabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroomi Watabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroomi Watabe more than expected).

Fields of papers citing papers by Hiroomi Watabe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroomi Watabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroomi Watabe. The network helps show where Hiroomi Watabe may publish in the future.

Co-authorship network of co-authors of Hiroomi Watabe

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroomi Watabe. A scholar is included among the top collaborators of Hiroomi Watabe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroomi Watabe. Hiroomi Watabe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 28
2
[Activity of fosfomycin against Escherichia coli O157:H7--morphological changes and production of Shiga toxins].
3
3 16
4
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
3
5
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
3
6 11
7 0
8 11
9 4
10 178
11 27
12 13
13 13
14 18
15 42
16
A new antibiotic SF2583A, 4-chloro-5-(3'-indolyl)oxazole, produced by Streptomyces.
13
17 28
18 35
19 53
20 17

About Hiroomi Watabe

Hiroomi Watabe is a scholar working on Microbiology, Molecular Medicine and Pharmacology, having authored 28 papers that have together received 590 indexed citations. Recurring topics across this work include Microbial Natural Products and Biosynthesis (7 papers), Antibiotic Resistance in Bacteria (6 papers) and Cancer therapeutics and mechanisms (5 papers). The work is most often cited by research in Pharmacology (164 citations), Molecular Medicine (46 citations) and Toxicology (25 citations). Hiroomi Watabe has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Minako Araake, K. Morikawa, Shigeru Morikawa, Takehiko Shibata, Tadahiko Ando, Masaji Sezaki, TAKASHI SHOMURA, Shinichi Kondo, T Iino and HARUO YAMAMOTO. Their work appears in journals such as Nature, Journal of Biological Chemistry and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026